Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

First filing for Astellas' SGLT2 inhibitor contender ipragliflozin, in Japan

This article was originally published in Scrip

Executive Summary

Astellas has landed the first blow in what will be a highly competitive market for sodium-glucose co-transporter 2 (SGLT2) inhibitors in Japan, with an approval filing for ipragliflozin (ASP1941) for type 2 diabetes.



Related Companies